Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097577 | 1.00 | NPC1 (0.55) | NPC1HRH3TSHRCYP3A4CYP2D6 | |
| SCHEMBL27097434 | 0.89 | HRH3 (0.43) | NPC1HRH3CYP2D6ALDH1A1 | |
| SCHEMBL27097534 | 0.89 | HRH3 (0.43) | NPC1HRH3CYP2D6ALDH1A1 | |
| SCHEMBL27097601 | 0.85 | NPC1 (0.50) | NPC1HRH3CYP2D6CYP1A2TDP1 | |
| SCHEMBL14654909 | 0.81 | NPC1 (0.60) | NPC1HRH3TSHRCYP2D6CYP1A2 | |
| SCHEMBL13939521 | 0.78 | NPC1 (0.88) | NPC1HRH3TSHRPSMB1PSMB5 | |
| SCHEMBL16016535 | 0.78 | NPC1 (0.88) | NPC1HRH3TSHRPSMB1PSMB5 | |
| SCHEMBL13367 | 0.77 | NPC1 (0.66) | NPC1HRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL27097462 | 0.74 | CYP1A2 (0.37) | NPC1HRH3TSHRCYP1A2ALDH1A1 | |
| SCHEMBL18912343 | 0.74 | NPC1 (0.56) | NPC1HRH3PSMB1PSMB5PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | NPC1 2550/4885HRH3 3443/4885TSHR 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.